Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
NCT ID: NCT01035307
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
NCT01642121
Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01150058
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421.
* To classify AML-based signal transduction mechanisms.
* To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples.
OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Genomic and Proteomic Profiling
gene expression analysis
microarray analysis
proteomic profiling
laboratory biomarker analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
microarray analysis
proteomic profiling
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia, meeting 1 of the following criteria:
* Primary induction failure (i.e., failed to achieve remission within the first 60 days of therapy)
* Relapsed disease (early or late)
* In continuous complete remission
* Previously enrolled on POG-9421
* Tissue samples available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norman J. Lacayo, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML09B2
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000659560
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02201
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML09B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.